COMMUNIQUÉS West-GlobeNewswire

D5 Health - Personalized Longevity Clinic Opens Its Doors in Raleigh, NC
03/11/2025
Innovative Clinic Offers Personalized Health Solutions to Optimize Vitality and Longevity Raleigh, NC, Nov. 03, 2025 (GLOBE NEWSWIRE) -- D5 Health , a personalized longevity clinic in Raleigh, is thrilled to announce [...]
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
03/11/2025
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP [...]
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
03/11/2025
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray) Oral presentation to report results from real world data on the [...]
Organogenesis Applauds CMS’s Significant Step In Payment Reform
03/11/2025
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond CANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/11/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 novembre 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Rendever Receives Nearly $4.5 Million in NIH Funding to Overcome Social Isolation for Older Adults while Supporting Caregivers
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in immersive technology for aging, has secured nearly $4.5 million in grant funding from the National Institutes of Health (NIH) to [...]
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
Two oral and seven poster presentations further support the CARVYKTI ® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., [...]
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
03/11/2025
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, [...]
Legal Steroids for Bulking, Cutting, Strength from CrazyBulk: Best Selling Legal Steroid Alternatives for Muscle Growth and Bodybuilding in 2025
03/11/2025
Crazy Bulk's Introduces Best Legal Steroid Alternatives Safe and Most Popular Legal Steroids for Muscle Building and Cutting supplements in 2025. It Help to Boost testosterone, and improve muscle growth, strength, and [...]
Zelluna ASA – Contemplates private placement
03/11/2025
Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR [...]
Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update
03/11/2025
Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 [...]
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
03/11/2025
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program [...]
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
03/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer [...]
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
03/11/2025
Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platform EVX-04 is a therapeutic cancer vaccine candidate designed for acute [...]
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
03/11/2025
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in [...]
Flare Therapeutics to Participate in Upcoming Investor Conferences in November
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
03/11/2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
NewGen Announces Proposed Reverse Merger with SAXA, Inc. in a $5 Billion Mining Asset Acquisition Deal, Involving Gold, Silver, and Rare Earth
03/11/2025
NewGen will issue 500 million shares at US$10 to acquire the mining assets, substantially boosting shareholders’ equity and transforming the merged entity into a multi-billion-dollar conglomerate BANGKOK, Nov. 03, 2025 [...]

Pages